Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
Phase 1
Completed
- Conditions
- Autoimmune Disease
- Interventions
- Drug: TAK-079Drug: Placebo to TAK-079
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 74
- Registration Number
- NCT02219256
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18113
- Registration Number
- NCT02211638
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
Phase 1
Terminated
- Conditions
- SafetyPharmacokineticsTolerabilityPharmacodynamics
- Interventions
- Drug: MLN3126Drug: MLN3126 Matched Placebo
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 23
- Registration Number
- NCT02209506
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 328
- Registration Number
- NCT02203916
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-935Drug: Placebo
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT02201056
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Phase 2
Completed
- Conditions
- Dengue Fever
- Interventions
- Drug: TDV Liquid Formulation 1Drug: TDV Liquid Formulation 2Drug: TDV IDT LyophilizedDrug: Placebo
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1002
- Registration Number
- NCT02193087
- Locations
- 🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Tekton Research, Austin, Texas, United States
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 246
- Registration Number
- NCT02181842
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Phase 3
Completed
- Conditions
- Multiple MyelomaAutologous Stem Cell Transplant
- Interventions
- Drug: PlaceboDrug: Ixazomib Citrate
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 656
- Registration Number
- NCT02181413
- Locations
- 🇦🇹
Elisabethinen Hospital Linz, Linz, Austria
🇦🇷Hospital Iturraspe, Santa Fe, Argentina
🇺🇸Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Azilsartan/Amlodipine
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1090
- Registration Number
- NCT02181816
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02176486
© Copyright 2025. All Rights Reserved by MedPath